Agenda
Our education program offers cutting-edge technical sessions, shedding light on the latest advancements in the pharma industry.
All session times are listed in Pacific Time (PT). Find your personal viewing time on the World Clock.
Filters
Selected filters:
-
Virtual
Mon, 27 Jan
Tue, 28 Jan
0830 – 0845
0845 – 0915
General Session
Joydeep Ganguly, Gilead Sciences, Inc.
Mobilizing a Digital Engineering Program: Practitioner Viewpoint
Over the past 2 years, Gilead has invested in multiple areas of Digital Engineering innovations: From large investments in Cloud-based applications, to a state-of-the-art Data Mesh, to 20+ advanced controls use cases that were deployed in production to accelerate scientific ambitions. This presentation reflects back on results, learnings, and lessons learned, and offers a practitioner playbook on how to start a digital innovation journey at scale. Leveraging use cases that applied AI/ML/large Language Models to engineering problems, this presentation also delves into emerging issues that need to be addressed in any organization’s innovation incubation journey.
0915 – 0945
General Session
Divakar Ramakrishnan, PhD, ConvaTec
Modern biotechnology starting with recombinant DNA (rDNA) technology and the manufacture of human insulin in 1982, is now 40+ years old. Since then, we have witnessed major research advances that led to monoclonal antibodies, synthetic peptides, and DNA and RNA based biopharmaceutical therapies. These advances were enabled by a rapid evolution of manufacturing processes from very cost-intensive bespoke or dedicated (product-specific) manufacturing facilities to common standardized & modular manufacturing platforms. We have also moved from biopharmaceutical products which started off as injectables in a glass vial to medicine now consisting of drug-delivery device combinations. With the advent of genetic medicine as a result of the Human Genome Project in the early 2000s, we are now witnessing a situation where modular clean room facilities next to hospital beds serve as today’s manufacturing platform, with the human body serving as the de facto medicine factory with DNA and RNA therapy. In the near future, we will witness an exponential ramp-up in innovation in areas ranging from chemical synthesis of biopharmaceuticals vs biosynthetic means, more cost-effective & scalable ways of enabling genetic medicines, improved ways of delivering DNA and RNA into cells as well as biopharmaceuticals transitioning from today’s injectables to orally ingestible medicine - all this will pave the way to further improve cost, access, and sustainability. In this seminar, I will share implications for ISPE engineers both by ways of research directions and education. I will also be sharing my lessons learned over ~ 25+ years at Eli Lilly, Cook Pharmica, Moderna, and to the present day at Convatec where my team and I are helping pioneer trusted medical solutions to improve the lives we touch.
0945 – 1000
1045 – 1115
Sustainability
Kelly LaCarubba, Takeda Pharmaceuticals Inc.
Polyfluoroalkyl substances (PFAS) are called 'forever chemicals' due to their longevity in the environment. A number of health-related outcomes have resulted in varying levels of environmental legislation for this class of materials. For example, the European Chemicals Agency (ECHA) has proposed a sweeping ban on PFAS within the European Economic Area (EEA). The implications for bio/pharmaceutical manufacturing of the ban in the EU encompass virtually the entire ecosystem of materials related to bio/pharmaceutical manufacturing. The Global Material Qualification organization within Takeda is taking an agile, systematic approach to assessing the risk environment created by the proposed ban and developing different response scenarios for Takeda to ensure our ability to provide life-transforming products to patients. This presentation will provide examples from the different facets of the Global Material Qualification approach to address the emerging challenges of the proposed PFAS ban in the EEA and beyond.
1115 – 1145
Solvent and Reagent In-Situ Reuse in Solid Phase Oligonucleotide Synthesis
A new SPOS fluid bed synthesizer was created that improves scalability, purity, and yield compared to traditional packed bed synthesizers, while also reducing solvent and waste. siRNA API was produced in GMP manufacturing with 9% higher SS purity than previous GMP batches and 3X less ACN wash solvent.
A new SPOS fluid bed synthesizer was created that improves scalability, purity, and yield compared to traditional packed bed synthesizers, while also reducing solvent and waste. siRNA API was produced in GMP manufacturing with 9% higher SS purity than previous GMP batches and 3X less ACN wash solvent.
1145 – 1215
Sustainability
Adam Goldstein, Thermo Fisher Scientific
A review of the plastic waste generation in the biopharmaceutical industry:
- Focusing on using single-use technologies in bioprocessing.
- Discuss concerns on sustainability based on plastic waste streams.
- Review the scale of plastic waste produced
- Review a bioprocess modeling package that can estimate the plastic usage for typical monoclonal antibody production at varying scales
- Discuss fluid handling components, filters, and resins.
- Show worldwide monoclonal antibody estimated total annual tons per year for bioprocess-related plastic waste generated by the industry.
- Inform sustainable practices within the biopharmaceutical industry and encourage the development of more sustainable disposable technologies.
Since adopting single-use technologies in biopharmaceutical manufacturing in the 1990s, there has been concern about the generated plastic waste streams. Estimates for plastic waste based on production quantities provide the biopharmaceutical industry with methods to predict waste produced and establish more sustainable disposal methods as single-use technology products expand into the mainstream production of biologics.
- Focusing on using single-use technologies in bioprocessing.
- Discuss concerns on sustainability based on plastic waste streams.
- Review the scale of plastic waste produced
- Review a bioprocess modeling package that can estimate the plastic usage for typical monoclonal antibody production at varying scales
- Discuss fluid handling components, filters, and resins.
- Show worldwide monoclonal antibody estimated total annual tons per year for bioprocess-related plastic waste generated by the industry.
- Inform sustainable practices within the biopharmaceutical industry and encourage the development of more sustainable disposable technologies.
Since adopting single-use technologies in biopharmaceutical manufacturing in the 1990s, there has been concern about the generated plastic waste streams. Estimates for plastic waste based on production quantities provide the biopharmaceutical industry with methods to predict waste produced and establish more sustainable disposal methods as single-use technology products expand into the mainstream production of biologics.
1345 – 1415
Facility Design & Delivery
Daryl Kern, PM Group
William Gantz, Bristol Myers Squibb
The pharmaceutical sector is in a state of constant development, currently focusing on creating and building facilities that can support a flexible array of products (in terms of variety, quantities, and sizes). Additionally, there is a growing interest among some stakeholders to manage the entire process from clinical to commercial stages, including full lifecycle products, within a single location, as well as the co-location of various different product modalities. These trends indicate a requirement for facilities that are more adaptable, enabling manufacturing operations to be quickly relocated, retrofitted, or expanded with efficiency. This adaptability not only enhances operational efficiency but also allows companies to respond swiftly to market demands and regulatory changes, ultimately fostering innovation and reducing time-to-market for new therapies. Bristol Myers Squibb aimed to establish a global standard for a new agile manufacturing concept that would facilitate multi-modality manufacturing across different products, volumes, and scales, while also enhancing future capacity decisions and regulatory adaptability. BMS collaborated with PM Group to create a standardized design that would separate the Building Shell from the interior layout, allowing for rapid deployment at both existing sites and new locations globally. In line with the design approach, the team aimed to standardize technology platforms and shift away from "purpose-built" designs to develop generic Process Modality floorplates (modules). The team leveraged a significant portion of BMS’s current product pipeline as a benchmark to appropriately size process capabilities and technologies that would be included in Flex Modules. These modules were then designed to meet Launch capabilities while also being versatile enough to expand and accommodate Commercial Scale capacities in the future. A nimble strategy will allow BMS to build globally adaptable shell structures within their network, irrespective of product choices. This will enable swifter market entry, while also allowing ease of future repurposing. This presentation summarizes the design methodology employed to bring the innovative Agile Manufacturing Concept to fruition.
1415 – 1445
Facility Design & Delivery
Andrew Tyner, SMRT Architects & Engineers
Chris McAllister, SMRT Architects & Engineers
Kevin Rosenthal, RayzeBio A Bristol Myers Squibb Company
The radiopharmaceutical field is rapidly transforming the treatment of life-threatening; however, this rapidly growing medical sector presents unique challenges and safety requirements in management and manufacturing, compared to other treatments. Radiopharmaceutical production necessitates highly specialized equipment and controlled environments equipped to safely store, prepare, fill, and package radioactive materials. Designing facilities to accommodate these critical processes demands a meticulous approach to safety, efficiency, and regulatory compliance. In addition, it is crucial for the design team to be embedded early in the process, with the client, as requirements vary from client to client and product to product. This dynamic session will explore essential considerations for creating a strategic framework that ensures the successful implementation of a radiopharmaceutical program. The owner and design team will share lessons learned and successes from designing RayzeBio's 63,000-square-foot manufacturing building in Indianapolis, IN. Attendees will leave the presentation armed with strategies and best practices for future building projects on their own campuses.
1445 – 1515
Facility Design & Delivery
John Kenneally, Bayer
Alfred Penfold, PM Group
Adapting a mAbs Production Facility for Production of a Gene Therapy
A study has shown that it is possible to adapt an existing mAbs drug substance facility for gene therapy production. The proposal was to use the existing mAbs facility for both mAbs and a gene therapy on a campaign basis with minimal changes to the facility. The study refers to the modifications that were required to accommodate both modalities and how the facility would operate differently to accommodate the gene therapy. Introducing an ATMP retrospectively in an existing mAbs facility presents a number of risks that had to be mitigated due to the additional segregation requirements needed for ATMPs. A meeting was held with the FDA to review the planned proposals, and it did not result in any major concerns.
A study has shown that it is possible to adapt an existing mAbs drug substance facility for gene therapy production. The proposal was to use the existing mAbs facility for both mAbs and a gene therapy on a campaign basis with minimal changes to the facility. The study refers to the modifications that were required to accommodate both modalities and how the facility would operate differently to accommodate the gene therapy. Introducing an ATMP retrospectively in an existing mAbs facility presents a number of risks that had to be mitigated due to the additional segregation requirements needed for ATMPs. A meeting was held with the FDA to review the planned proposals, and it did not result in any major concerns.
1600 – 1700
General Session
Daniela Andrade, Amgen
Sarah Braet, Takeda California
Mitra Cruz, Kite Pharma, Inc.
Powered and Led by Women in Pharma ®
This session features a comprehensive discussion on the impact of digital transformation in the pharmaceutical and biotech industries. It emphasizes that digital transformation is not merely about adopting new technologies, but involves a fundamental shift in mindset and operations to enhance value for patients and customers. Presenters from Kite Pharma, Amgen, and Takeda LA, will share their experiences and insights on manufacturing, capital projects, and digital transformation initiatives. The presentation will delve into the holistic control strategies needed for the life sciences industry, the opportunities in manufacturing, and the necessary organizational changes to support employees, particularly women, in adapting to new technologies. The panel discussion will further explore these themes, with each panelist sharing professional insights and personal stories to inspire young professionals and women in the industry.
1815 – 2015
General Session
Sam Guhan, Amgen
Jeff Davis, Genentech
Drew Johnston, Bayer
Shanshan Liu, No Deviation Pte Ltd
Liz Dooley, Johnson & Johnson
Engage with industry leaders at the Executive Forum Dinner and Panel Discussion. This unique event offers attendees the chance to hear with industry leaders as they share their insights. Featuring thought-provoking discussions and valuable perspectives from esteemed panelists, this dinner provides a unique opportunity to exchange ideas and forge meaningful connections. Don’t miss this opportunity to gain actionable takeaways and expand your professional network.
Dinner and Panel Discussion included in with In-Person All Access Pass.
Virtual attendees have access to the live-streamed panel discussion.
For all other registrants, the add-on fee for the Executive Forum Dinner and Panel Discussion is $250
Dinner and Panel Discussion included in with In-Person All Access Pass.
Virtual attendees have access to the live-streamed panel discussion.
For all other registrants, the add-on fee for the Executive Forum Dinner and Panel Discussion is $250
Sam Guhan
Senior Vice President, Global Engineering
Amgen
Amgen
Jeff Davis
Vice President, SSF Manufacturing Site Head
Genentech
Genentech
Drew Johnston
Vice President Site Engineering
Bayer
Bayer
Shanshan Liu
Technical Director
No Deviation Pte Ltd
No Deviation Pte Ltd
Liz Dooley
Senior Director, Global Engineering & Technology
Johnson & Johnson
Johnson & Johnson
0830 – 0845
0845 – 0915
General Session
Gunter Baumgartner, Takeda Pharmaceuticals International AG
Reaching New Summits in Pharmaceutical Manufacturing with Pharma 4.0 and Digital Transformation
The pharmaceutical industry is facing a multitude of external challenges, including cost pressures from healthcare systems, such as the Inflation Reduction Act (IRA), patent cliffs, and changes in the global political landscape, exemplified by the BioSecure Act. Amidst these challenges, Pharma 4.0 is emerging as one of the paths to sustainably bringing innovation to patients. The ISPE's frameworks have supported and encouraged steps towards digitalization and outlined benefits and use cases. However, the pharma industry has been slow to change compared to other sectors. Already in 2021, the FDA was stating that "some industries are now well into Industry 3.0, but in many ways the pharmaceutical industry is still very much transitioning into it." With two-thirds of drug shortages historically still attributed to quality-related issues, the opportunities to continue the digitalization journey are plentiful.
Exploring the root causes, many companies are lost on the journey, either organizationally or technologically, with some unsure of where to start, others pursuing multiple pilot projects, and some finding that the technology journey is just the beginning of the transformation journey. Additionally, the industry faces a tension between decentralized, democratic, and duplicative organizing principles versus centralized, cumbersome kingdoms.
Takeda has been on this journey for many years and has taken the challenges head-on. From the Facility of the Year (FOYA) awards for Singen and Linz awards in 2022 and 2024 to public commitments to sustainability Pharma 4.0, Takeda's approach has enabled the implementation of numerous technologies and new ways of working. As the industry faces an increasingly diverse portfolio and an ever-complex manufacturing landscape, Pharma 4.0 will be a key driver of growth to meet patients’ demands. We would like to explore some of the good practices we learned on our digital transformation journey.
The pharmaceutical industry is facing a multitude of external challenges, including cost pressures from healthcare systems, such as the Inflation Reduction Act (IRA), patent cliffs, and changes in the global political landscape, exemplified by the BioSecure Act. Amidst these challenges, Pharma 4.0 is emerging as one of the paths to sustainably bringing innovation to patients. The ISPE's frameworks have supported and encouraged steps towards digitalization and outlined benefits and use cases. However, the pharma industry has been slow to change compared to other sectors. Already in 2021, the FDA was stating that "some industries are now well into Industry 3.0, but in many ways the pharmaceutical industry is still very much transitioning into it." With two-thirds of drug shortages historically still attributed to quality-related issues, the opportunities to continue the digitalization journey are plentiful.
Exploring the root causes, many companies are lost on the journey, either organizationally or technologically, with some unsure of where to start, others pursuing multiple pilot projects, and some finding that the technology journey is just the beginning of the transformation journey. Additionally, the industry faces a tension between decentralized, democratic, and duplicative organizing principles versus centralized, cumbersome kingdoms.
Takeda has been on this journey for many years and has taken the challenges head-on. From the Facility of the Year (FOYA) awards for Singen and Linz awards in 2022 and 2024 to public commitments to sustainability Pharma 4.0, Takeda's approach has enabled the implementation of numerous technologies and new ways of working. As the industry faces an increasingly diverse portfolio and an ever-complex manufacturing landscape, Pharma 4.0 will be a key driver of growth to meet patients’ demands. We would like to explore some of the good practices we learned on our digital transformation journey.
0915 – 0945
0945 – 1000
1045 – 1115
Technology;Digital Transformation & Pharma 4.0™
Peter Luke, Novo Nordisk A/S
This abstract presents a best-in-class collaboration between one of the largest separation manufacturers in the world and Novo Nordisk A/S. This presentation will showcase the successful co-creation of filtration technology - used in the pulp/paper, wine, and juice industry – for use in API manufacturing. Results include operational savings, full process closure, and enhanced quality. The culmination of this collaborative effort will be presented at the ISPE Facility of the Future Conference, emphasizing the transformative impact of cross-industry innovation, particularly in meeting the stringent requirements of pharmaceutical Good Manufacturing Practice (GMP) standards. The close co-creation between Novo Nordisk A/S and the manufacturer has fast-forwarded the manufacturer's GMP understanding by decades, expanding the vendors supporting our industry. The presentation will spotlight the outcomes of this collaboration, including the innovative partnership highlighting the potential for potential, when we look to other industries for inspiration.
1115 – 1145
Technology;Digital Transformation & Pharma 4.0™
Rod Hoffman, AstraZeneca
Giuseppe Menin, Ing. Punzenberger COPA-DATA GmbH
The new manufacturing paradigms in life sciences pose considerable challenges to the engineers who have to deal with automation and digitalization. For example, the operational flexibility required in biotech, the modules that make up the production processes in flow chemistry and the inefficiencies caused by the numerous manual operations in cell therapies. But what do these production sectors have in common? They consist of modules specialized in specific functionalities linked together to produce a specific product. Modules produced by different suppliers, often incompatible from a digitization point of view. For some years now, the concept of 'modular production' has been gaining ground, whereby production processes are subdivided into intelligent modules capable of communicating with each other in a standardized manner. These are combined with a software application capable of automatically recognizing the various modules and 'orchestrating' their operation according to a user-defined sequence. We call it “plug & produce”. To support this production concept, a standard called MTP - Module Type Package (VDI/VDE/NAMUR 2658) - has been developed and has proven its worth in recent years. The authors of this contribution are members of the Plug & Produce working group of the ISPE Pharma 4.0 CoP. The presentation will introduce the advantages of this new approach based on the MTP standard by giving concrete examples of the application of modular automation in the life sciences field, contained within a concept paper that is currently being developed.
1145 – 1215
Technology;Digital Transformation & Pharma 4.0™
Sebastian Scheler, Innerspace GmbH
Jeff Gensler, Kindeva Drug Delivery
To accelerate greenfield projects, the necessary production processes must be developed quickly without compromising safety and risk management; however, due to their inherent complexity, the risks in the processes are often manifold and can only be identified with a considerable amount of time and resources - this delays the market launch of important drugs and is often associated with major corrections, as some process weaknesses remain unidentified, jeopardizing the entire commercialization process. The main reason for the high effort and error-prone nature of process design and risk assessment is that they have to be created largely manually. The presentation will introduce a novel process simulation approach that utilizes a generic database around so-called "process-frames" (process-microsteps) to develop data-driven recommendations for process design and autogenerated risk management insights with unprecedented accuracy. By linking the "process frames" with numerous production data, a self-learning software has been created that also identifies potential risks for new process ideas and helps to achieve robust process design and CCS more efficiently. The presentation presents a case study from Kindeva and shows how "Frame-by-Frame Risk Profiling" has significantly accelerated process design and risk management - both prerequisites for faster plant and operational readiness.
1345 – 1415
Innovations in Manufacturing
Christian Lavarreda, Syntegon
Integral to time to market in the (bio)pharmaceutical industry, the need for enhanced functionality and compliance in manufacturing operations continues to grow rapidly. Biopharma companies are under intense pressure to bring progressively sophisticated production capacity online in ever-shorter timelines. This presentation will delve into the role that modular hardware and automation frameworks are increasingly playing in helping meet this need, in particular by enabling the implementation of sophisticated control strategies. We provide a detailed description of these frameworks and the symbiotic relationship between modularity and advanced control in today's biopharma environment. We present a detailed case study on the implementation of such a strategy in upstream bioprocessing (microbial fermentation), covering the orchestration of overall operations, the optimization of the production processes, and the impact on compliance given regulatory considerations. As we venture into the future of pharmaceutical production, this presentation addresses the accelerating modularity trend and the implications for industry.
1415 – 1445
Innovations in Manufacturing
Raymond Boyse, PhD, Eli Lilly
Declan Gavin, PhD
1445 – 1515
Innovation districts are evolving from their role as hubs for translational research and commercialization into dynamic ecosystems that prepare, attract, and retain talent. At the forefront of this shift is the 16 Tech Innovation District in Indianapolis. Opened in 2021, 16 Tech is cultivating pathways to jobs in advanced industries with the same intentionality that it is attracting the resources and partners to take an idea from concept to commercialization. Located in diverse and historic neighborhoods of downtown Indianapolis, the 50-acre emerging innovation district is already home to 300 member companies, including all three of Indiana’s Tier 1 research universities, and recognized anchors like the Indiana Biosciences Research Institute and the Emerging Manufacturing Collaboration Center. 16 Tech is also the future headquarters of Heartland BioWorks, a nationally recognized hub for biotech manufacturing.
Key topics will include:
- Place-based development and community impact.
- Experiential learning as a bridge between talent and industry.
- Workforce development programs and educational partnerships to build a pipeline of future talent.
Key topics will include:
- Place-based development and community impact.
- Experiential learning as a bridge between talent and industry.
- Workforce development programs and educational partnerships to build a pipeline of future talent.
1530 – 1545
General Session
Anthony Trujillo, Total Validation Services, Inc.
1545 – 1615
General Session
Francesco Intoccia, CSL Behring
Michele Ghinizzini, Sanofi
Gunter Baumgartner, Takeda Pharmaceuticals International AG
The ISPE Facility of the Year Awards (FOYA) program celebrates cutting-edge pharmaceutical facilities that exemplify innovation, operational excellence, and a commitment to advancing patient care. Celebrating it’s 20th anniversary, this prestigious award honors facilities that demonstrate exceptional dedication to quality, efficiency, and cutting-edge technology, contributing significantly to the pharmaceutical industry and global health outcomes.
In this session, we will introduce the 2025 FOYA Submission Finalists—projects that have met the FOYA program's rigorous standards and exemplify the industry's highest achievements. Presented by a select panel from the FOYA Judging Committee, this session provides attendees with an exclusive, first-look at these facilities from around the world.
1615 – 1645
General Session
Kevin Trivett, Eli Lilly and Company
The pharmaceutical industry is on the cusp of a transformative era, driven by advancements in technology and innovative approaches to facility design and operation. This will all improve the safety of our operations, improve our quality performance, and advance our ability to scale and reach more patients with life-saving medicine.
This presentation will explore some of Lilly’s examples of advancing our Manufacturing Innovation agenda to reach more patients and will include aspects such as Facilities of the Future elements in Lilly’s investment agenda, advancing technology & standardization in our manufacturing processes to enhance operational excellence, and our people investment plans building capability and unleashing our employees’ potential for the future.
Key topics will include:
- Manufacturing innovation with new facilities
- Examples in our Device and Packaging operations leveraging technology
- Leveraging Standardization to accelerate performance
- People investment plans to build capability
This presentation will explore some of Lilly’s examples of advancing our Manufacturing Innovation agenda to reach more patients and will include aspects such as Facilities of the Future elements in Lilly’s investment agenda, advancing technology & standardization in our manufacturing processes to enhance operational excellence, and our people investment plans building capability and unleashing our employees’ potential for the future.
Key topics will include:
- Manufacturing innovation with new facilities
- Examples in our Device and Packaging operations leveraging technology
- Leveraging Standardization to accelerate performance
- People investment plans to build capability
1645 – 1700
Speaker Qualifications
Speakers selected to present at ISPE events are leading professionals in their fields. However, it may be necessary to make substitutions. Every possible effort will be made to substitute a speaker with comparable qualifications. Every precaution is taken to ensure accuracy. ISPE does not assume responsibility for information distributed or contained in these events, or for any opinion expressed.
Agenda Changes
Agenda is subject to change. Last minute changes due to functional, private, or organizational needs may be necessary. The event organizer accepts no liability for any additional costs caused by a change of the agenda.